Single-Dose Bioequivalence Study of Rivaroxaban-Containing Medicinal Products in Healthy Volunteers

Single-Dose Bioequivalence Study of Rivaroxaban-Containing Medicinal Products in Healthy Volunteers

Therapeutically, new oral anticoagulants (NOACs) are considered to be non-inferior or superior to vitamin K antagonists (warfarin). NOACs are included in current guidelines for the treatment of various cardiovascular diseases. Rivaroxaban medicinal products have been shown to effectively fight throm...

Full description

Bibliographic Details
Main Authors: G. N. Gildeeva, A. A. Chaplenko, V. I. Yurkov, E. S. Stepanova
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2022-10-01
Series:Безопасность и риск фармакотерапии
Subjects:
rivaroxaban
pharmacokinetics
bioequivalence
new oral anticoagulants
safety profile
Online Access:https://www.risksafety.ru/jour/article/view/316

Internet

https://www.risksafety.ru/jour/article/view/316

Similar Items